Adjuvant Capital is a venture capital firm dedicated to improving global health by financing innovative life science technologies that address high-burden public health challenges. Founded by veterans of the Gates Foundation's Global Health Investment Fund, the firm focuses on diseases such as malaria, tuberculosis, and HIV/AIDS, as well as maternal and child health, nutrition, and reproductive and sexual health. By leveraging venture capital strategies, Adjuvant Capital aims to accelerate the global availability of impactful medical innovations, ensuring they are accessible to those who need them most.

The firm is backed by leading strategic investors and alternative asset managers who understand the global public health landscape, providing invaluable domain expertise and support on top of their capital commitments.